Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Perazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 4/20 | 0.76 |
| ▸ | ADRA2A known ✓ | P08913 | 4/20 | 0.76 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.76 |
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.76 |
| ▸ | ADRA2C known ✓ | P18825 | 4/20 | 0.76 |
| ▸ | DRD1 known ✓ | P21728 | 4/20 | 0.76 |
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.76 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.76 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.76 |
| ▸ | ADRA1A known ✓ | P35348 | 4/20 | 0.76 |
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.76 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 0.76 |
| ▸ | SLC6A3 known ✓ | Q01959 | 4/20 | 0.76 |
| ▸ | KCNH2 known ✓ | Q12809 | 4/20 | 0.76 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.76 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.76 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.76 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.76 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.76 |
| ▸ | OPRM1 known ✓ | P35372 | 3/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perazine SCHEMBL6644457 | 1.00 | KDM1A (0.97) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| Perazine SCHEMBL29390464 | 0.98 | KDM1A (1.00) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| Perazine SCHEMBL147165 | 0.98 | KDM1A (1.00) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| SCHEMBL6859184 | 0.95 | KDM1A (0.94) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| Perazine SCHEMBL10531680 | 0.90 | KDM1A (0.84) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| SCHEMBL10973127 | 0.90 | KDM1A (0.84) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| Prochlorperazine SCHEMBL1041250 | 0.89 | DRD2 (0.98) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| Prochlorperazine SCHEMBL2506559 | 0.89 | DRD2 (0.98) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| SCHEMBL2615404 | 0.88 | KDM1A (0.80) | KDM1AHTR1AADRA2ACHRM1DRD2 | |
| SCHEMBL7594811 | 0.87 | KDM1A (0.78) | KDM1AHTR1AADRA2ACHRM1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| CN-103415286-A | Compounds and methods for treating pain | AKRON MOLECULES GMBH | 2013-11-27 | — | — | CN | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| EP-2571501-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2013-03-27 | — | — | EP | disclosed |
| EP-2531191-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POSTOPERATIVE PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-12-12 | — | — | EP | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
| WO-2011144721-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011095584-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POSTOPERATIVE PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-11 | — | — | WO | disclosed |
| EP-1784167-A2 | MULTI-LAYER TABLETS AND BIOADHESIVE DOSAGE FORMS | Spherics, Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006031420-A2 | MULTI-LAYER TABLETS AND BIOADHESIVE DOSAGE FORMS | SPHERICS, INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| WO-2006026556-A2 | BIOADHESIVE RATE-CONTROLLED ORAL DOSAGE FORMULATIONS | SPHERICS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1575564-A1 | SOLID DISPERSIONS COMPRISING A HYGROSCOPIC AND/OR DELIQUESCENT DRUG | Pharmacia Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1575563-A1 | NON-HYGROSCOPIC FORMULATION COMPRISING A HYDROSCOPIC DRUG | Pharmacia Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050013856-A1 | Solid dispersions comprising a hygroscopic and/or deliquescent drug | PHARMACIA CORPORATION | 2005-01-20 | — | — | US | disclosed |
| WO-2004060353-A9 | SOLID DISPERSIONS COMPRISING A HYGROSCOPIC AND/OR DELIQUESCENT DRUG | PHARMACIA CORP (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040197411-A1 | Acceptably non-hygroscopic formulation intermediate comprising a hygroscopic drug | PHARMACIA CORPORATION | 2004-10-07 | — | — | US | disclosed |
| WO-2004060353-A1 | SOLID DISPERSIONS COMPRISING A HYGROSCOPIC AND/OR DELIQUESCENT DRUG | PHARMACIA CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060352-A1 | NON-HYGROSCOPIC FORMULATION COMPRISING A HYDROSCOPIC DRUG | PHARMACIA CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | HTR1A 477/4885ADRA2A 221/4885CHRM1 924/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | HTR1A 477/4885ADRA2A 221/4885CHRM1 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.